A Phase 3 interventional study of Ponesimod and Placebo in Multiple Sclerosis, sponsored by Actelion. Terminated at 119 sites in 20 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-05-18.
Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,192 studies in Multiple Sclerosis with a site in United States — 184 open to participants now, 259 under way, 23 of them phase 3. Multiple Sclerosis · United States.
Among the 1,192 studies in Multiple Sclerosis with a site in United States, this one is the 203rd largest by enrollment of the 879 interventional ones that give a count, is one of 60 that started in 2017, is one of 127 in phase 3, and was the 555th registered.
3,272 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →184 of the 1,192 studies in Multiple Sclerosis with a site in United States are open now. Recruiting first, the newest first:
Sundance Biosciences, Inc. · Sites in United States
Ages 18–70
Genentech, Inc. · Sites in United States, Puerto Rico
Ages 18–65
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 40–70
University of Texas at Austin · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 432 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 213 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,192 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 142 · Phase 2 191 · Phase 3 142 · Phase 4 82
First in 1976; this study’s year is marked. 60 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 136 is above the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.
Median enrollment 50 across the 879 interventional studies, 100 across the 302 observational. Of the 818 that completed or were terminated, 332 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
376 of 1,192 have an industry lead sponsor. The 10 most frequent:
This study is registered under Actelion, one of the names counted as Johnson & Johnson. Under that name alone:
Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
Johnson & Johnson has 7 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
78 of the studies in Multiple Sclerosis with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05134441Phase 3Immunic AGStudy to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | 2026-11 |
| NCT05877963Phase 3TG Therapeutics, Inc.Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | 2027-01-21 |
| NCT06136728Phase 3MGH Institute of Health ProfessionsDalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis | 2027-05 |
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT07325292Phase 3SanofiNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | 2027-07-15 |
Add all 78 to your calendar (.ics) → With an account.
Among the 1,192 studies in Multiple Sclerosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical study compares the efficacy, safety, and tolerability of therapy with ponesimod vs placebo in subjects with active RMS who are treated with DMF (Tecfidera®).
The study will assess the efficacy, safety, and tolerability of add-on therapy with ponesimod 20 mg vs placebo in adult participants with active relapsing multiple sclerosis (RMS) who are treated with dimethyl fumarate (DMF). Approximately 600 participants who have been receiving DMF for at least 6 months will be randomized in a 1:1 ratio to ponesimod 20 mg or placebo. The study consists of the following study periods: Pre-randomization period; Treatment period; Post-treatment observation period. The study includes one ponesimod treatment arm at the maintenance dose of 20 mg o.d. corresponding to the optimal dose when used as monotherapy based on the Phase 2 dose-finding trial and its ongoing extension. The study includes a placebo comparator arm, but all patients will remain on DMF background therapy throughout the study. Moreover, participants who experience a confirmed relapse or an event of 24-week confirmed disability accumulation (DMF) while on study drug will have the option to switch to an alternative treatment. The treatment period has a variable duration from a minimum of 60 weeks (for the last subject randomized) to a maximum of 156 weeks for the first subjects randomized in the trial and includes a gradual up-titration of ponesimod from a 2 mg starting dose to a 20 mg maintenance dose over a period of 14 days. The total duration of the study will be approximately up to 167 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ponesimod
Drug: Ponesimod
Placebo
Other: Placebo
One tablet of ponesimod 20 mg administered orally once daily in the morning from Day 15 to EOT. To reduce the first-dose effect of ponesimod, an uptitration scheme will be implemented from Day 1 to Day 14 (with dose strength increasing from 2 mg to 20 mg).
One tablet of matching placebo administered orally once daily in the morning
Annualized Confirmed Relapse Rate (ARR)
Relapse: occurrence of acute episode of one or more new or worsened symptoms of Multiple sclerosis (MS), not associated with fever/infection and lasting 24 hours after stable 30 days period. Confirmed relapse: increase from baseline at least 0.5 point Expanded Disability Status Scale (EDSS) score or increase of one point in one, two or three Functional Systems (FS), excluding bowel/bladder and cerebral/mental FS. EDSS and FS scores are based on neurological examination for assessing its impairment in MS. Among eight FS, seven are ordinal clinical rating scales ranging from 0-5 or 6 with higher scale indicates overall functional impairment assessing Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel/Bladder and Cerebral functions. Rating individual FS scores is used to rate EDSS in conjunction with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10(death due to MS).
Time frame: Through study completion, an average of 68 weeks
Percentage of Participants With 12-Week Confirmed Disability Accumulation (CDA) as Assessed by Kaplan Meier Estimate at Week 96
Percentage of participants with 12-week CDA as assessed by Kaplan Meier estimate at week 96 was defined as an increase of at least 1.5 in Expanded Disability Status Scale (EDSS) for participants with a baseline EDSS score of 0.0 or an increase of at least 1.0 in EDSS for participants with a baseline EDSS score of 1.0 to 5.0, or an increase of at least 0.5 in EDSS for participants with a baseline EDSS score greater than or equal to (\>=) 5.5, which was confirmed after 12 weeks. Baseline EDSS was defined as the last EDSS score recorded prior to randomization. EDSS is an ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10 (death due to MS).
Time frame: Week 96
Percentage of Participants Experiencing a Confirmed Relapse as Assessed by Kaplan Meier Estimate at Week 96
Percentage of participants experiencing a confirmed relapse as assessed by Kaplan Meier estimate at week 96 was reported. The time to first confirmed relapse (in days) is defined as \[Date of first confirmed relapse minus Date of randomization plus 1\] in days. Relapse: Occurrence of acute episode of one or more new symptoms or worsened symptoms of Multiple sclerosis (MS), not related with fever/infection and lasting 24 hours after 30 days stable period.
Time frame: Week 96
Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability
An AE is any untoward medical event that occurs in a participants administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
Time frame: Up to 147 Weeks
| Milestone | Ponesimod Plus Dimethyl Fumarate (DMF) | Placebo Plus Dimethyl Fumarate (DMF) |
|---|---|---|
| Started | 68 | 68 |
| Treated | 67 | 68 |
| Randomized analysis set | 68 | 68 |
| Completed | 0 | 0 |
| Not completed | 68 | 68 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Physician decision | 3 | 3 |
| Withdrew: Withdrawal by subject | 15 | 7 |
| Withdrew: Sponsor's decision | 50 | 57 |
Relapse: occurrence of acute episode of one or more new or worsened symptoms of Multiple sclerosis (MS), not associated with fever/infection and lasting 24 hours after stable 30 days period. Confirmed relapse: increase from baseline at least 0.5 point Expanded Disability Status Scale (EDSS) score or increase of one point in one, two or three Functional Systems (FS), excluding bowel/bladder and cerebral/mental FS. EDSS and FS scores are based on neurological examination for assessing its impairment in MS. Among eight FS, seven are ordinal clinical rating scales ranging from 0-5 or 6 with higher scale indicates overall functional impairment assessing Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel/Bladder and Cerebral functions. Rating individual FS scores is used to rate EDSS in conjunction with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10(death due to MS).
| Relapses per year | Ponesimod Plus Dimethyl Fumarate (DMF) | Placebo Plus Dimethyl Fumarate (DMF) |
|---|---|---|
| Annualized Confirmed Relapse Rate (ARR) | 0.237 (0.144 to 0.391) | 0.187 (0.109 to 0.322) |
Percentage of participants with 12-week CDA as assessed by Kaplan Meier estimate at week 96 was defined as an increase of at least 1.5 in Expanded Disability Status Scale (EDSS) for participants with a baseline EDSS score of 0.0 or an increase of at least 1.0 in EDSS for participants with a baseline EDSS score of 1.0 to 5.0, or an increase of at least 0.5 in EDSS for participants with a baseline EDSS score greater than or equal to (\>=) 5.5, which was confirmed after 12 weeks. Baseline EDSS was defined as the last EDSS score recorded prior to randomization. EDSS is an ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10 (death due to MS).
| Percentage of participants with a CDA. | Ponesimod Plus Dimethyl Fumarate (DMF) | Placebo Plus Dimethyl Fumarate (DMF) |
|---|---|---|
| Percentage of Participants With 12-Week Confirmed Disability Accumulation (CDA) as Assessed by Kaplan Meier Estimate at Week 96 | 18.7 (8.7 to 37.6) | 11.9 (4.6 to 28.8) |
Percentage of participants experiencing a confirmed relapse as assessed by Kaplan Meier estimate at week 96 was reported. The time to first confirmed relapse (in days) is defined as \[Date of first confirmed relapse minus Date of randomization plus 1\] in days. Relapse: Occurrence of acute episode of one or more new symptoms or worsened symptoms of Multiple sclerosis (MS), not related with fever/infection and lasting 24 hours after 30 days stable period.
| Percentage of Participants | Ponesimod Plus Dimethyl Fumarate (DMF) | Placebo Plus Dimethyl Fumarate (DMF) |
|---|---|---|
| Percentage of Participants Experiencing a Confirmed Relapse as Assessed by Kaplan Meier Estimate at Week 96 | 33.6 (19.5 to 53.8) | 25.7 (13.4 to 46.1) |
An AE is any untoward medical event that occurs in a participants administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
| Participants | Ponesimod Plus Dimethyl Fumarate (DMF) | Placebo Plus Dimethyl Fumarate (DMF) |
|---|---|---|
| Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability | 48 | 53 |
Collected over Up to End of treatment + 15 days (maximum up to 147 Weeks). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ponesimod Plus Dimethyl Fumarate (DMF) | 0/67 (0%) | 6/67 (9%) | 45/67 (67.2%) |
| Placebo Plus Dimethyl Fumarate (DMF) | 1/68 (1.5%) | 7/68 (10.3%) | 41/68 (60.3%) |
| Event | Ponesimod Plus Dimethyl Fumarate (DMF) | Placebo Plus Dimethyl Fumarate (DMF) |
|---|---|---|
| Gastroenteritis BacterialInfections and infestations | 1/67 | 0/68 |
| Multiple InjuriesInjury, poisoning and procedural complications | 1/67 | 0/68 |
| Procedural NauseaInjury, poisoning and procedural complications | 1/67 | 0/68 |
| Road Traffic AccidentInjury, poisoning and procedural complications | 1/67 | 0/68 |
| Testicle AdenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/67 | 0/68 |
| SeizureNervous system disorders | 1/67 | 0/68 |
| Status EpilepticusNervous system disorders | 1/67 | 0/68 |
| Urinary RetentionRenal and urinary disorders | 1/67 | 0/68 |
| Right Ventricular FailureCardiac disorders | 0/67 | 1/68 |
| InfluenzaInfections and infestations | 0/67 | 1/68 |
| Event | Ponesimod Plus Dimethyl Fumarate (DMF) | Placebo Plus Dimethyl Fumarate (DMF) |
|---|---|---|
| NasopharyngitisInfections and infestations | 6/67 | 13/68 |
| DizzinessNervous system disorders | 7/67 | 1/68 |
| Upper Respiratory Tract InfectionInfections and infestations | 3/67 | 7/68 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/67 | 7/68 |
| HeadacheNervous system disorders | 6/67 | 6/68 |
| Back PainMusculoskeletal and connective tissue disorders | 2/67 | 6/68 |
| ParaesthesiaNervous system disorders | 0/67 | 6/68 |
| BronchitisInfections and infestations | 5/67 | 3/68 |
| Urinary Tract InfectionInfections and infestations | 4/67 | 5/68 |
| FatigueGeneral disorders | 4/67 | 4/68 |
Randomized Analysis Set included all participants who were randomized in this study.
| Age, Categorical(Participants) | Ponesimod Plus Dimethyl Fumarate (DMF) | Placebo Plus Dimethyl Fumarate (DMF) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 68 | 68 | 136 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Ponesimod Plus Dimethyl Fumarate (DMF) | Placebo Plus Dimethyl Fumarate (DMF) | Total |
|---|---|---|---|
| Mean | 37.8 ± 9.1 | 38.1 ± 9.1 | 37.9 ± 9.07 |
| Sex: Female, Male(Participants) | Ponesimod Plus Dimethyl Fumarate (DMF) | Placebo Plus Dimethyl Fumarate (DMF) | Total |
|---|---|---|---|
| Female | 43 | 46 | 89 |
| Male | 25 | 22 | 47 |
| Ethnicity (NIH/OMB)(Participants) | Ponesimod Plus Dimethyl Fumarate (DMF) | Placebo Plus Dimethyl Fumarate (DMF) | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 2 | 6 |
| Not Hispanic or Latino | 61 | 61 | 122 |
| Unknown or Not Reported | 3 | 5 | 8 |
| Race/Ethnicity, Customized(Participants) | Ponesimod Plus Dimethyl Fumarate (DMF) | Placebo Plus Dimethyl Fumarate (DMF) | Total |
|---|---|---|---|
| Asian | 0 | 1 | 1 |
| Black or African American | 3 | 1 | 4 |
| Other | 0 | 2 | 2 |
| Unknown or Not Reported | 1 | 1 | 2 |
| White | 64 | 63 | 127 |
| Region of Enrollment(Participants) | Ponesimod Plus Dimethyl Fumarate (DMF) | Placebo Plus Dimethyl Fumarate (DMF) | Total |
|---|---|---|---|
| AUSTRIA | 5 | 7 | 12 |
| BELGIUM | 2 | 0 | 2 |
| BULGARIA | 2 | 2 | 4 |
| CANADA | 0 | 1 | 1 |
| CZECH REPUBLIC | 16 | 17 | 33 |
| FRANCE | 4 | 6 | 10 |
| GERMANY | 4 | 6 | 10 |
| GREECE | 4 | 6 | 10 |
| HUNGARY | 1 | 0 | 1 |
| ITALY | 5 | 4 | 9 |
| MEXICO | 1 | 0 | 1 |
| POLAND | 4 | 5 | 9 |
| PORTUGAL | 1 | 0 | 1 |
| RUSSIAN FEDERATION | 4 | 2 | 6 |
| SPAIN | 2 | 3 | 5 |
| UNITED KINGDOM | 5 | 4 | 9 |
| UNITED STATES | 8 | 5 | 13 |
Showing the first 100 of 119 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2017 to primary completion in Mar 2020, 35 months.
Results were first posted in May 2021, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ponesimod